Ownership stake · Activity not yet classified

Insight Pharmaceuticals

Transaction overview

Reported completed

Announced:

Exact closing date not established.

Swander Pace reported finalizing its sale of Insight Pharmaceuticals to Prestige Brands Holdings.

Selected source-supported transactions; coverage is incomplete. Announcements do not establish completion or that a deal is still pending. Sponsor activity and operating-business transactions are distinct from adviser acquisitions. Unclassified activity is excluded from adviser-only counts.

Source evidence

  1. Swander Pace Capital Finalizes Sale of Insight Pharmaceuticals for $750 Million ↗

    Swander Pace Capital · Published Sep 3, 2014

    Reports a finalized sale and includes a same-day sale reference. The proposal conservatively leaves the exact legal closing-date field unset.

No firms selected for comparison.
Insight Pharmaceuticals · RIA Monitor